Can the cancer team see who needs psychosocial attention?
A returned score is not the end of the job. Cancer services need to see who needs psychosocial attention, why, who owns the next step, what has happened, and whether the person is getting better.
At a glance
Detect. Understand. Review again.
- Detect
Distress screen plus mood context
- Drivers
Problem domains, fear, needs, sleep, money
- Review
Clinician-owned next step and follow-up
A clinically important result should not sit unused in the record.
Distress, mood, fear of recurrence, unmet needs and financial strain often arrive as separate forms. Without a shared view of who is waiting, what the scores point to and who is responsible, elevated results become another number. Start with a closed loop: detect, establish drivers, review, and look again.
- Detect distress
- Establish drivers
- Review change over time
A clear purpose for every step.
Start with the information your clinicians need. Use these steps to plan the questionnaire work around the consultation.
- 01
Detect who needs attention
Use a brief distress screen and supporting mood measures so the team can see who is asking for help. A screening cutoff is evidence for clinician consideration, not a diagnosis.
- 02
Establish what is driving the problem
Problem domains, fear of recurrence, unmet needs, sleep, fatigue, body image, cognition and financial strain answer different questions. Choose the smallest set that explains the person's situation.
- 03
Keep ownership and change in view
Returned forms stay with the responsible clinician. Repeat the same measures when you need to see whether the person is improving. Lirena does not assign care or decide clinical risk.
What each measure brings to the review.
These measures support a psychosocial loop in cancer care. Compare what each contributes. Scores remain screening or outcome evidence for a clinician, not diagnoses or treatment plans.
NCCN Distress Thermometer
A 0-10 distress screen for the past week, including today. Published oncology screening evidence commonly uses 4 or greater as a prompt for clinician review.
A distress rating is a screen, not a psychiatric diagnosis. Pair it with the problem list when you need to see what is driving the score.
Read Distress Thermometer catalogue details →Depressive symptom frequency over two weeks. In cancer populations, screening evidence around a total of 8 is a prompt for clinician review rather than a diagnosis of depression.
Review item 9 directly under local protocol. Lirena does not monitor responses in real time or decide clinical risk.
Read PHQ-9 catalogue details →Anxiety symptom frequency over two weeks. Cancer-service screening evidence around a total of 8 is metadata for clinician consideration, not an anxiety diagnosis.
A brief anxiety screen does not replace clinical interview, medical context or comorbidity review.
Read GAD-7 catalogue details →Nine items on the severity of worry that cancer will come back. Screening evidence around a total of 22 is a prompt for clinician review.
Fear of recurrence is a reported experience. The total is not a disorder label and not a treatment recommendation.
Read FCRI-SF catalogue details →Unmet supportive-care needs across physical, psychological, sexual, care and information domains, so the team can see what the person is asking for help with.
Moderate or high need on an item is a signal for clinician review of that domain, not a diagnosis.
Read SCNS-SF34 catalogue details →A practical starting point for your service.
Start with the closed loop, not a test library
The featured measures exist so a cancer team can detect distress, see likely drivers and review change. They are not a catalogue to send in full by default.
Keep screening evidence distinct from diagnosis
Oncology-specific cutoffs are published screening metadata tied to a population and purpose. They never mean the person has a disorder, a prognosis or an AI risk score.
Your team's questions, answered.
Assessment purposes, clinical responsibilities and the next step for your service.
Does a Distress Thermometer score of 4 diagnose psychiatric illness?
No. A score of 4 or greater is published screening evidence that a clinician should review the person and the problem list. It is not a diagnosis.
Does PHQ-9 or GAD-7 diagnose depression or anxiety in cancer care?
No. Oncology screening evidence around a total of 8 is a prompt for clinician consideration. Diagnosis, differential diagnosis and treatment decisions remain with the responsible clinician.
Will Lirena predict survival, treatment success or psychiatric risk?
No. Lirena does not claim survival benefit, predict treatment outcome, diagnose a disorder or produce an AI psychiatric risk score. It supports assignment, collection, deterministic scoring, clinician review and export.
Do we have to send every oncology measure to every patient?
No. Start with the distress screen and add driver measures that answer the clinical question. The smallest defensible set is better than a default battery.
How do we choose a plan for our clinic?
Compare the current plans on the pricing page. Bring your expected assessment volume, required measures and review process to a call if you need help choosing.
What happens after Get Started or Book Call?
Get Started takes you to account setup. The Free plan requires no card. Book Call lets you choose a time to discuss your clinic's workflow. Please bring measure names and process questions, without patient records or responses.
Give the cancer team a psychosocial loop they can run.
Bring the measures you already use. Talk through detection, drivers, ownership and follow-up before choosing a plan.